| 51 |
19669737 | CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. | 2009 Sep |
3 |
| 52 |
19925388 | Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. | 2009 Sep |
2 |
| 53 |
18445991 | The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. | 2008 |
2 |
| 54 |
18816302 | Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). | 2008 Aug |
4 |
| 55 |
18971529 | Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. | 2008 Aug |
4 |
| 56 |
17305793 | CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. | 2007 Mar |
1 |
| 57 |
17344941 | Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients. | 2007 Jan-Feb |
1 |
| 58 |
17516991 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. | 2007 Jun |
3 |
| 59 |
16445595 | Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. | 2006 Feb |
1 |
| 60 |
16635054 | Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. | 2006 Apr |
1 |
| 61 |
16783563 | Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. | 2006 Jul |
2 |
| 62 |
16278191 | Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. | 2005 Aug |
1 |
| 63 |
14600250 | Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. | 2004 Feb |
1 |
| 64 |
15100169 | The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. | 2004 May |
4 |
| 65 |
15197523 | CYP2C9 genetic variants and losartan oxidation in a Turkish population. | 2004 Jul |
9 |
| 66 |
15289788 | Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. | 2004 Aug |
8 |
| 67 |
15592335 | Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. | 2004 Dec |
1 |
| 68 |
29793229 | The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. | 2004 Dec |
1 |
| 69 |
12520632 | Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. | 2003 Jan |
2 |
| 70 |
12820813 | Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. | 2003 Jun |
3 |
| 71 |
12899669 | A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. | 2003 Aug |
1 |
| 72 |
14504849 | Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. | 2003 Nov |
4 |
| 73 |
11823761 | Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. | 2002 Jan |
10 |
| 74 |
12081638 | Paeoniae Radix, a traditional Chinese medicine, and CYP2C9 activity. | 2002 Jun |
1 |
| 75 |
12207639 | Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. | 2002 Aug |
1 |
| 76 |
12235444 | Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. | 2002 Sep |
4 |
| 77 |
12359989 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. | 2002 Oct |
3 |
| 78 |
12405866 | Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | 2002 |
1 |
| 79 |
11368292 | Clinical pharmacokinetics of fluvastatin. | 2001 |
1 |
| 80 |
11408373 | Role of CYP2C9 polymorphism in losartan oxidation. | 2001 Jul |
10 |
| 81 |
11829203 | The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. | 2001 Dec |
2 |
| 82 |
10678291 | Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. | 2000 Feb |
1 |
| 83 |
10877007 | In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. | 2000 May |
1 |
| 84 |
9920790 | Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. | 1999 Jan 27 |
2 |
| 85 |
10197301 | The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. | 1999 Apr |
2 |
| 86 |
10562462 | Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. | 1999 Nov |
1 |
| 87 |
9542475 | Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. | 1998 Mar |
2 |
| 88 |
9551703 | Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. | 1998 Feb |
2 |
| 89 |
7736913 | Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. | 1995 Feb |
2 |